Company intelligence / Profile preview

Paz

Tel Aviv, Israel

Ownership: Private
Development stage: Other

Overview

Paz Therapeutics is an early-stage biotechnology company focused on developing novel cancer immunotherapies by targeting the tumor microenvironment. The company utilizes a proprietary discovery platform to identify and modulate specific pathways that allow tumors to evade the immune system. By reprogramming the cellular interactions within the tumor site, Paz Therapeutics aims to enhance the efficacy of existing treatments and provide new options for patients with resistant solid tumors. Headquartered in Israel, the company is currently advancing its lead programs through pre-clinical validation.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Paz.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paz.

Explore the full profile